Year To Quarter End Consolidated Statement Of Comprehensive Income

Carna Biosciences, Inc. - Filing #7338599

Concept 2024-01-01 to
2024-03-31
2023-01-01 to
2023-03-31
Year to quarter end consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
-398,890,000 JPY
-519,210,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
-229,000 JPY
-101,000 JPY
Deferred gains or losses on hedges
19,240,000 JPY
-615,000 JPY
Foreign currency translation adjustment
20,316,000 JPY
1,648,000 JPY
Other comprehensive income
39,327,000 JPY
932,000 JPY
Comprehensive income
-359,563,000 JPY
-518,278,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
-359,563,000 JPY
-518,278,000 JPY
Comprehensive income attributable to non-controlling interests
JPY
JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.